The Traderszone Network

Published in TZ Latest News 12 November, 2017 by The TZ Newswire Staff

Better Buy: Exelixis, Inc. vs. Novartis AG

Novartis (NYSE: NVS) stands out as one of the biggest pharma companies with a broad array of products, including several of the most powerful cancer drugs on the market. Exelixis (NASDAQ: EXEL) only has three products on the market right now, but it ranks as one of the most promising rising stars in the treatment of cancer.

read more